Index


standard operating procedure (SOP), pS80 stationary phase, pS81 steady state, pS81 stock solution, pS81 Study Director, pS81 Study Monitor, pS81 study plan, pS81 supercritical fluid chromatography (SFC), pS82 superficially porous (core-shell) particle, pS82 supernatant, pS82 supported-liquid extraction, pS82 surface plasmon resonance (SPR), pS82 surrogate analyte, pS82 surrogate matrix, pS82 surrogate peptide, pS83 system priming, pS83 system suitability, pS83 tandem mass spectrometry, pS83 tandem quadrupole mass spectrometry, pS84 targeted analysis, pS84 targeted quantitation, pS85 therapeutic drug monitoring, pS86 tiered approach, pS86 time-of-flight mass spectrometry (TOF-MS), pS86 tissue distribution, pS86 top down proteomics, pS86 total drug, pS86 total ion chromatogram (TIC), pS87 turbulent flow, pS87 ultra-high-performance liquid chromatography (UHPLC), pS87 undersampling, pS87 unknown, pS87 upper limit of quantification (ULOQ), pS87 US Food and Drug Administration (US FDA), pS90 validation report, pS90 van Deemter equation, pS90 very-high-pressure liquid chromatography (VHPLC), pS90 volumetric absorptive microsampling, pS90 weighting factor, pS90 white paper, pS91 whole blood, pS91


future science group www.future-science.com S103


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117